Alpha Tau Medical(DRTS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

DRTS Alpha Tau Medical

Post-Mkt 12-22 18:13:45 EST

5.10

+0.03

+0.59%

盘后5.15

+0.05+0.98%

18:03 EST

High5.20	Low4.99	Vol295.63K
Open5.12	D1 Closing5.07	Amplitude4.14%
Mkt Cap434.85M	Tradable Cap291.37M	Total Shares85.26M
T/O1.54M	T/O Rate0.52%	Tradable Shares57.13M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"DRTS","market":"US","secType":"STK","nameCN":"Alpha Tau Medical","latestPrice":5.1,"timestamp":1766437200000,"preClose":5.07,"halted":0,"volume":295627,"hourTrading":{"tag":"盘后","latestPrice":5.15,"preClose":5.1,"latestTime":"18:03 EST","volume":273,"amount":1393.349958,"timestamp":1766444602531},"delay":0,"floatShares":57132114,"shares":85264100,"eps":-0.52193,"marketStatus":"Post-Mkt","change":0.03,"latestTime":"12-22 18:13:45 EST","open":5.12,"high":5.2,"low":4.99,"amount":1536105.8287515,"amplitude":0.04142,"askPrice":5.2,"askSize":1000,"bidPrice":4.57,"bidSize":90,"shortable":3,"etf":0,"ttmEps":-0.52193,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1766451600000},"marketStatusCode":4,"adr":0,"exchange":"NASDAQ","adjPreClose":5.07,"preHourTrading":{"tag":"盘前","latestPrice":5.2,"preClose":5.07,"latestTime":"09:29 EST","volume":36117,"amount":198314.040726,"timestamp":1766413771016},"postHourTrading":{"tag":"盘后","latestPrice":5.15,"preClose":5.1,"latestTime":"18:03 EST","volume":273,"amount":1393.349958,"timestamp":1766444602531},"volumeRatio":1.962005,"impliedVol":0.5227,"impliedVolPercentile":0.3636},"requestUrl":"/m/hq/s/DRTS/tweets","defaultTab":"tweets","newsList":[{"id":"2592901486","title":"Alpha Tau Medical to Present Corporate Update at J.P. Morgan Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2592901486","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592901486?lang=en_us&edition=fundamental","pubTime":"2025-12-18 22:01","pubTimestamp":1766066511,"startTime":"0","endTime":"0","summary":"Alpha Tau Medical Ltd. will present a corporate overview and update at the J.P. Morgan 2026 Healthcare Conference on January 15, 2026, in San Francisco, CA. CEO Uzi Sofer and CFO Raphi Levy are scheduled to speak at 11:15am PT and will also host institutional investor meetings during the event. A webcast of the presentation will be available on the company's website.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alpha Tau Medical Ltd. published the original content used to generate this news brief via GlobeNewswire  on December 18, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251218:nNDLccVYwj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","LU2210150020.SGD","LU2095319765.USD","SG9999014013.SGD","SG9999014039.USD","IE00BGHQF748.EUR","IE00BKPKM429.USD","BK4585","BK4588","DRTS","NDAQ","LU0314104364.USD","SG9999014021.USD","BK4082","IE00B64PRP62.GBP","BK4112","SG9999014005.SGD","LU2210149790.SGD"],"gpt_icon":0},{"id":"2590590950","title":"Is Alpha Tau Medical (NASDAQ:DRTS) Using Debt Sensibly?","url":"https://stock-news.laohu8.com/highlight/detail?id=2590590950","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590590950?lang=en_us&edition=fundamental","pubTime":"2025-12-11 18:27","pubTimestamp":1765448873,"startTime":"0","endTime":"0","summary":"The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6021000-choice1-main-header/1585186659638","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6021000-choice1-main-header/1585186659638"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nasdaq-drts/alpha-tau-medical/news/is-alpha-tau-medical-nasdaqdrts-using-debt-sensibly","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/healthcare/nasdaq-drts/alpha-tau-medical/news/is-alpha-tau-medical-nasdaqdrts-using-debt-sensibly","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["TQQQ","USJW.SI","SQQQ",".IXIC","QID","NQmain","PSQ","TSYW.SI","QLD","DRTS","EBIT","BK4082","USAW.SI","NVIW.SI","MNQmain"],"gpt_icon":1},{"id":"2590537284","title":"Alpha Tau Medical Up Over 12%, on Track for Highest Close Since January 2023 -- Data Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2590537284","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590537284?lang=en_us&edition=fundamental","pubTime":"2025-12-11 03:45","pubTimestamp":1765395900,"startTime":"0","endTime":"0","summary":"Alpha Tau Medical Ltd  is currently at $4.76, up $0.53 or 12.53%. --Would be highest close since Jan. 12, 2023, when it closed at $4.83. --On pace for largest percent increase since Jan. 13, 2025, when it rose 14.55%. --Up 53.55% year-to-date; on pace for best year on record . --Down 68.89% from its all-time closing high of $15.30 on March 29, 2022. --Up 55.05% from 52 weeks ago , when it closed at $3.07. --Up 94.29% from its 52-week closing low of $2.45 on April 7, 2025. --Traded as high as $5.07; highest intraday level since Jan. 13, 2023, when it hit $5.10. --Up 19.86% at today's intraday high; largest intraday percent increase since June 28, 2024, when it rose as much as 23.41%","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","DRTS"],"gpt_icon":0},{"id":"2590537546","title":"Alpha Tau Medical Is Maintained at Buy by Citigroup","url":"https://stock-news.laohu8.com/highlight/detail?id=2590537546","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590537546?lang=en_us&edition=fundamental","pubTime":"2025-12-11 03:25","pubTimestamp":1765394700,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/DRTS/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 10, 2025 14:25 ET (19:25 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DRTS"],"gpt_icon":0},{"id":"2590520344","title":"Alpha Tau Medical Ltd - Treats First Patient in Glioblastoma Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2590520344","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590520344?lang=en_us&edition=fundamental","pubTime":"2025-12-09 22:04","pubTimestamp":1765289044,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251209:nFWN3XF0PJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4082","DRTS"],"gpt_icon":0},{"id":"2590344326","title":"Alpha Tau Medical Treats First Glioblastoma Patient with Alpha DaRT in U.S. Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2590344326","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590344326?lang=en_us&edition=fundamental","pubTime":"2025-12-09 22:00","pubTimestamp":1765288826,"startTime":"0","endTime":"0","summary":"Alpha Tau Medical Ltd. announced the successful treatment of the first patient in its pilot study using the Alpha DaRT technology for recurrent glioblastoma multiforme  at The James Cancer Hospital at The Ohio State University. This marks the first time Alpha DaRT has been used to treat brain cancer. The study is part of Alpha Tau's broader strategy to address unmet needs in cancer treatment, particularly for GBM, which has a poor prognosis and limited treatment options. The results of this study have not yet been presented.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alpha Tau Medical Ltd. published the original content used to generate this news brief via GlobeNewswire  on December 09, 2025, and is solely responsible for the infor","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251209:nNDL7sLY3q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LU2210149790.SGD","NDAQ","BK4585","IE00BGHQF748.EUR","BK4082","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","IE00BKPKM429.USD","BK4112","LU0314104364.USD","SG9999014005.SGD","SG9999014021.USD","LU2095319765.USD","LU2210150020.SGD","SG9999014013.SGD","SG9999014039.USD","DRTS"],"gpt_icon":0},{"id":"2588887176","title":"Alpha Tau Medical Launches U.S. Clinical Trial of Alpha DaRT for Pancreatic Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2588887176","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588887176?lang=en_us&edition=fundamental","pubTime":"2025-12-04 22:00","pubTimestamp":1764856813,"startTime":"0","endTime":"0","summary":"Alpha Tau Medical Ltd. has announced the initiation of a multi-center clinical trial in the United States to evaluate its Alpha DaRT alpha-radiation cancer therapy for patients with newly diagnosed pancreatic cancer. The first patient was treated in September 2025, and the trial is expected to enroll up to 30 participants, with patient recruitment anticipated to be completed by the end of the first quarter of 2026. Additionally, two abstracts related to this research-focused on the feasibility, safety, efficacy, and immune response to Alpha DaRT in advanced pancreatic cancer-have been accepted for presentation at the 2026 American Society of Clinical Oncology  Gastrointestinal Cancers Symposium, scheduled for January 8-10, 2026. Results from a completed pilot trial in Montreal, Canada, will be presented at this event.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, th","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nNDL2Dm847:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210150020.SGD","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","BK4588","LU2095319765.USD","NDAQ","DRTS","IE00BKPKM429.USD","BK4585","LU2210149790.SGD","BK4082","BK4112","IE00BGHQF748.EUR","LU0314104364.USD"],"gpt_icon":0},{"id":"2588056264","title":"Alpha Tau Medical Wins FDA Approval to Begin Prostate Cancer Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2588056264","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588056264?lang=en_us&edition=fundamental","pubTime":"2025-12-02 22:00","pubTimestamp":1764684016,"startTime":"0","endTime":"0","summary":"Alpha Tau Medical Ltd. has received FDA approval for an Investigational Device Exemption  to initiate a pilot study of its Alpha DaRT technology for patients with locally recurrent prostate cancer. This marks the company's fifth active IDE in the United States. The clinical trial will enroll up to 12 U.S. patients to primarily evaluate the safety of the treatment, with secondary objectives assessing efficacy through biochemical and clinical measures of disease progression and overall survival. No funding or grant from other organizations was mentioned.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alpha Tau Medical Ltd. published the original content used to generate this news brief via GlobeNewswire  on December 02, 2025, and is sole","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nNDL7vmCYh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","IE00B3QW5Z07.USD","BK4585","IE00BKPKM429.USD","BK4082","BK4112","LU2210149790.SGD","IE00B64PRP62.GBP","LU0314104364.USD","LU2210150020.SGD","NDAQ","DRTS","LU2095319765.USD","IE00BGHQF748.EUR"],"gpt_icon":0},{"id":"2588056248","title":"Alpha Tau Receives FDA Approval to Initiate a Trial for Patients With Locally Recurrent Prostate Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2588056248","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588056248?lang=en_us&edition=fundamental","pubTime":"2025-12-02 22:00","pubTimestamp":1764684001,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nTUA2MNHBJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["DRTSW","BK4082","DRTS"],"gpt_icon":0},{"id":"2588773457","title":"Alpha Tau to Participate in December Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2588773457","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588773457?lang=en_us&edition=fundamental","pubTime":"2025-12-01 22:00","pubTimestamp":1764597600,"startTime":"0","endTime":"0","summary":"JERUSALEM, Dec.  01, 2025  (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (\"Alpha Tau\", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT, ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/01/3197086/0/en/Alpha-Tau-to-Participate-in-December-Investor-Conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","DRTS"],"gpt_icon":0},{"id":"2585464419","title":"Alpha Tau Medical Price Target Maintained With a $9.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2585464419","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585464419?lang=en_us&edition=fundamental","pubTime":"2025-11-24 20:44","pubTimestamp":1763988240,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/DRTS/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 24, 2025 07:44 ET (12:44 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DRTS"],"gpt_icon":0},{"id":"2585469621","title":"Promising Developments and Strategic Trials Support Buy Rating for Alpha Tau Medical Ltd.","url":"https://stock-news.laohu8.com/highlight/detail?id=2585469621","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585469621?lang=en_us&edition=fundamental","pubTime":"2025-11-24 19:36","pubTimestamp":1763984163,"startTime":"0","endTime":"0","summary":"Alpha Tau Medical Ltd, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Yi Chen from H.C. Wainwright reiterated...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/promising-developments-and-strategic-trials-support-buy-rating-for-alpha-tau-medical-ltd-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/promising-developments-and-strategic-trials-support-buy-rating-for-alpha-tau-medical-ltd-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["DRTS"],"gpt_icon":0},{"id":"2585150027","title":"Alpha Tau Medical Reports Q3 2025 Results and Advances in Cancer Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2585150027","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585150027?lang=en_us&edition=fundamental","pubTime":"2025-11-21 05:38","pubTimestamp":1763674689,"startTime":"0","endTime":"0","summary":"Alpha Tau Medical Ltd ( ($DRTS) ) has issued an update. On November 20, 2025, Alpha Tau Medical Ltd. announced its third quarter 2025 financial res...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/alpha-tau-medical-reports-q3-2025-results-and-advances-in-cancer-therapy?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/alpha-tau-medical-reports-q3-2025-results-and-advances-in-cancer-therapy?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4082","DRTS"],"gpt_icon":0},{"id":"2585150936","title":"Alpha Tau Medical Q3 EPS $(0.14) Misses $(0.12) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2585150936","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585150936?lang=en_us&edition=fundamental","pubTime":"2025-11-21 05:19","pubTimestamp":1763673597,"startTime":"0","endTime":"0","summary":"Alpha Tau Medical (NASDAQ:DRTS) reported quarterly losses of $(0.14) per share which missed the analyst consensus estimate of $(0.12) by 21.74 percent. This is a 40 percent decrease over losses of $(0.10) per share from","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/48991168/alpha-tau-medical-q3-eps-0-14-misses-0-12-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Alpha Tau Medical Q3 EPS $(0.14) Misses $(0.12) Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DRTS"],"gpt_icon":0},{"id":"2585150508","title":"Alpha Tau reports Q3 EPS (32c), consensus (12c)","url":"https://stock-news.laohu8.com/highlight/detail?id=2585150508","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585150508?lang=en_us&edition=fundamental","pubTime":"2025-11-21 05:10","pubTimestamp":1763673047,"startTime":"0","endTime":"0","summary":"“The third quarter has seen a fantastic continuation of our accelerating momentum at Alpha Tau (DRTS), as the pace of patient treatments continues ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/alpha-tau-reports-q3-eps-32c-consensus-12c-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/alpha-tau-reports-q3-eps-32c-consensus-12c-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4082","DRTS"],"gpt_icon":0},{"id":"2585157742","title":"Alpha Tau Medical reports third quarter 2025 financial results","url":"https://stock-news.laohu8.com/highlight/detail?id=2585157742","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585157742?lang=en_us&edition=fundamental","pubTime":"2025-11-21 05:08","pubTimestamp":1763672881,"startTime":"0","endTime":"0","summary":"Alpha Tau Medical Ltd. reported research and development expenses of $22.5 million for the nine months ended September 30, 2025, up from $19.5 million in the same period in 2024, primarily due to increased employee compensation, benefits, and project costs. The company had a cash, cash equivalents, and deposits balance of $75.9 million as of the end of the third quarter of 2025. Key business developments during the period included the receipt of a radioactive material license for its New Hampshire manufacturing facility, progress in U.S. multi-center pilot studies for pancreatic cancer, and ongoing patient recruitment for its pivotal ReSTART trial in recurrent cutaneous squamous cell carcinoma.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal ad","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251120:nNDL6md92X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DRTS","BK4082"],"gpt_icon":0},{"id":"2584338941","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2584338941","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584338941?lang=en_us&edition=fundamental","pubTime":"2025-11-20 19:00","pubTimestamp":1763636400,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.·Jacobs Solutions Inc.                              4Q      1.68   6:45 AM. ·ZIM Integrated Shpg                              3Q       .77   7:00 AM","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DKS","AUNA","AMTM","ADI","DELL","AMBA","CENT","BBWI","DOOO","FRO","BLBD","BJ","CAL","ADSK","BBW","VIPS","MOG.B","BBY","AZTA","ESTC","EMBC","A","ALLT","FIVE","GAP","CLCO","CLFD","ZS","CDLR","BULL","CPRT","ANF","CMBT","BLRX","BURL","FLNC","BBAR","DRTS","ATAT","WMT","GGAL","NTES","DLTR","ZM","ATKR","CENTA","ARWR","DE"],"gpt_icon":1},{"id":"2584296886","title":"Oramed Pharmaceuticals reports $65 million net income for nine months ended September 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2584296886","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584296886?lang=en_us&edition=fundamental","pubTime":"2025-11-17 21:56","pubTimestamp":1763387811,"startTime":"0","endTime":"0","summary":"Oramed Pharmaceuticals Inc. reported unaudited financial results for the nine months ended September 30, 2025. The company recorded a pre-tax net income of $65.0 million, compared to a net loss of $6.1 million for the same period last year. Basic earnings per share were $1.30 and diluted earnings per share were $1.26. Total assets rose by 42% year-over-year, from $155.3 million to $220.5 million. Research and development expenses decreased from $4.9 million to $4.4 million, while general and administrative expenses increased from $4.3 million to $5.0 million. During the period, Oramed completed a full $100 million principal repayment from Scilex and reported substantial unrealized gains from its equity holdings in Alpha Tau Medical Ltd. and other investments.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only a","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251117:nNDL4PSslg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","DRTS","ORMP","BK4082"],"gpt_icon":0},{"id":"2582649523","title":"Alpha Tau to Participate at Jefferies Global Healthcare Conference in London","url":"https://stock-news.laohu8.com/highlight/detail?id=2582649523","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582649523?lang=en_us&edition=fundamental","pubTime":"2025-11-11 21:30","pubTimestamp":1762867800,"startTime":"0","endTime":"0","summary":"JERUSALEM, Nov.  11, 2025  (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (\"Alpha Tau\", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT, ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/11/3185416/0/en/Alpha-Tau-to-Participate-at-Jefferies-Global-Healthcare-Conference-in-London.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DRTS","LABU","BK4137","HCSG","BK4082","LU0029874061.USD","BK4588","XLV","BK4581","BK4585","LU0128526141.USD","XBI"],"gpt_icon":0},{"id":"2577395076","title":"Alpha Tau Medical Price Target Maintained With a $9.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2577395076","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577395076?lang=en_us&edition=fundamental","pubTime":"2025-10-22 22:50","pubTimestamp":1761144600,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/DRTS/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 22, 2025 10:50 ET (14:50 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DRTS"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.alphatau.com","stockEarnings":[{"period":"1week","weight":0.004},{"period":"1month","weight":0.3777},{"period":"3month","weight":0.2396},{"period":"6month","weight":0.7483},{"period":"1year","weight":0.6224},{"period":"ytd","weight":0.6355}],"compareEarnings":[{"period":"1week","weight":-0.0017},{"period":"1month","weight":0.0271},{"period":"3month","weight":0.0254},{"period":"6month","weight":0.1452},{"period":"1year","weight":0.1612},{"period":"ytd","weight":0.1613}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. The company's Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; preclinical or pending clinical studies for brain and other cancers; and preclinical studies for hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. Alpha Tau Medical Ltd. was incorporated in 2015 and is headquartered in Jerusalem, Israel.","yearOnYearQuotes":[{"month":1,"riseRate":1,"avgChangeRate":0.182703},{"month":2,"riseRate":0,"avgChangeRate":-0.162067},{"month":3,"riseRate":0,"avgChangeRate":-0.092438},{"month":4,"riseRate":0.5,"avgChangeRate":-0.086097},{"month":5,"riseRate":0.75,"avgChangeRate":0.093963},{"month":6,"riseRate":1,"avgChangeRate":0.079508},{"month":7,"riseRate":0.25,"avgChangeRate":-0.00683},{"month":8,"riseRate":0.5,"avgChangeRate":-0.059828},{"month":9,"riseRate":0.5,"avgChangeRate":0.052507},{"month":10,"riseRate":0,"avgChangeRate":-0.106065},{"month":11,"riseRate":0.25,"avgChangeRate":0.002718},{"month":12,"riseRate":0.5,"avgChangeRate":0.024724}],"exchange":"NASDAQ","name":"Alpha Tau Medical","nameEN":"Alpha Tau Medical"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Alpha Tau Medical(DRTS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Alpha Tau Medical(DRTS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Alpha Tau Medical,DRTS,Alpha Tau Medical股票,Alpha Tau Medical股票老虎,Alpha Tau Medical股票老虎国际,Alpha Tau Medical行情,Alpha Tau Medical股票行情,Alpha Tau Medical股价,Alpha Tau Medical股市,Alpha Tau Medical股票价格,Alpha Tau Medical股票交易,Alpha Tau Medical股票购买,Alpha Tau Medical股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Alpha Tau Medical(DRTS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Alpha Tau Medical(DRTS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction